This is the authors' abstract. We don't add key points for this paper.
Introduction. The study assessed the seroprevalence of Hepatitis E virus (HEV) markers in different at-risk groups within the Republic of Moldova. The risk groups included blood donors, hemodialysed patients, medical workers, tuberculosis (TB) patients, and intravenous drug users (IDUs). Material and methods. A cross-sectional descriptive-epidemiological study was conducted from 2019 to 2023, with participants randomly selected from different risk groups. Blood samples were collected and tested using ELISA for Anti-HEV IgG and IgM markers. Seroprevalence was calculated with 95% confidence intervals, and statistical analyses were conducted using Epi Info 7.2 software. Results. Among 794 tested blood donors, 9.6% (95% CI: 7.7-11.8) were positive for Anti-HEV IgG, indicating past exposure, and 8.3% (95% CI: 6.3-10.8) for Anti-HEV IgM, suggesting recent infection. Hemodialyzed patients had a significantly higher seroprevalence: 45.8% (95% CI: 34.8–57.1) for Anti-HEV IgG and 21.6% (95% CI: 9.8–38.2) for Anti-HEV IgM. Medical workers exhibited moderate IgG prevalence at 11.8% (95% CI: 9.1-15.0) and substantially higher IgM prevalence at 38.1% (95% CI: 26.1-51.2). TB patients had lower IgG (11.9%, 95% CI: 7.8-17.2) and IgM (7.8%, 95% CI: 3.6-14.3) prevalences. IDUs had a notable IgG prevalence of 20.5% (95% CI: 12.6-30.4) but no detectable IgM. Conclusions. This study highlights the significant burden of hepatitis E virus infection among at-risk populations in the Republic of Moldova.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Sajin et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: